

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	MAIL STOP NEW APPLICATION
)	
Francois Schutze et al.)	Group Art Unit: Unassigned
)	
Application No.: Unassigned)	Examiner: Unassigned
)	
Filed: April 21, 2005)	Confirmation No.: Unassigned
)	
For: USE OF TENATOPRAZOLE FOR THE)	
TREATMENT OF)	
GASTROESOPHAGEAL REFLUX)	
DISEASE)	

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.


The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date April 21, 2005

By: 
E. Joseph Gess
Registration No. 28,510

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Substitute for form 1449A/PTO & 1449B/PTO

**FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number Unassigned 10/531900
Filing Date April 21, 2005
First Named Inventor Francois Schutze et al.
Examiner Name Unassigned
Attorney Docket Number 032013-120

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	WO 02/072070	A1	PCT	09-19-2002							
	WO 01/28558	A1	PCT	04-26-2001							
	WO 99/59544	A2	PCT	11-25-1999							
	WO 00/50037	A1	PCT	08-31-2000							
	WO 98/16228	A1	PCT	04-23-1998							

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
✓	Anonymous, "Tenatoprazole: benatoprazole, TU 199," DRUGS IN R&D, 3(4); pp. 276-277, 2002
✓	UCHIYAMA et al., "The Long-lasting Effect of TU-199, a Novel H ⁺ , K ⁺ -ATPase Inhibitor, on Gastric Acid Secretion in Dogs," JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 51, no. 4, pp. 457-464, XP008018962, April 1999
✓	HOWDEN et al., "Appropriate Acid Suppression for Optimal Healing of Duodenal Ulcer and Gastro-Oesophageal Reflux Disease", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 29, no. SUPPL. 201, pp. 79-82 XP008018957, 1994
✓	WILKINSON et al., "Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy," ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 13, no. 9, pp. 1205-1209; XP002246271, 1999
✓	HENDREL et al., "Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease? ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 9, no. 6, p. 693-697, 1995
✓	DE CAESTECKER, "Medical therapy for supraesophageal complications of gastroesophageal reflux," AMERICAN JOURNAL OF MEDICINE, vol. 103, no. 5, Part A, pp. 138S-143S, XP001159192, November 24, 1997
✓	CENGIA et al., "Nocturnal Chronic Cough and Gerd: Clinical Correlations and Significance of Abnormal Proximal Esophageal Reflux", GASTROENTEROLOGY, vol. 116, No. 4, Part 2, Page A134, XP008018958, April 1999
✓	MAY et al., "Estraesophageal manifestations of reflux disease concerning the airways", VERDAUUNGSKRANKHEITEN, vol. 16, No. 6, pp. 267-270; XP008018331, November 1998
✓	WORTH et al., "Interrelationships between gastro-esophageal reflux and airway diseases-pathophysiology, diagnostic and therapeutic possibilities," ATEMWEGS- UND LUNGENKRANKHEITEN, vol. 20, No. 12, pp. 697-700, XP008018329, 1994
✓	RODRIGUEZ-TELLEZ M. et al., "Posterior laryngitis: Effects of treatment with omeprazole along.", REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, vol. 94, no. 3, pp. 127-130, XP008018960, 2002

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO

FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	Unassigned 10/531900
Filing Date	April 21, 2005
First Named Inventor	Francois Schutze et al.
Examiner Name	Unassigned
Attorney Docket Number	032013-120

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.